Case report: A novel perspective on the treatment of primary tracheal small cell carcinoma: a patient's experience with immuno-combined EP therapy and literature review
- PMID: 38348051
- PMCID: PMC10859462
- DOI: 10.3389/fimmu.2024.1356268
Case report: A novel perspective on the treatment of primary tracheal small cell carcinoma: a patient's experience with immuno-combined EP therapy and literature review
Abstract
Tracheal small cell carcinoma (SCC) is a rare malignancy, for which the optimal treatment strategy has yet to be determined. Currently, treatment largely aligns with the therapeutic guidelines established for small cell lung cancer, although numerous unresolved issues remain. This paper details a case study of a patient with Stage IIIB primary tracheal SCC, who was treated with an immune-combined etoposide-platinum(EP) regimen. This treatment offers valuable insights into innovative approaches for managing such malignancies. Furthermore, the study includes a comprehensive literature review to better contextualize the findings. The patient, admitted on May 2, 2023, had been experiencing persistent symptoms of airway discomfort for 15 days. A bronchoscopy performed on May 4 revealed tracheal SCC, classified as T4N2M0, IIIB. Following the CAPSTONE-1 study's methodology, the patient underwent six cycles of PD-L1(adebrelimab) combined with EP therapy, leading to significant relief of symptoms and the eventual disappearance of the tracheal mass.
Keywords: adebrelimab; etoposide-platinum regimen; immune-combined therapy; optimal treatment strategy; tracheal small cell carcinoma.
Copyright © 2024 Chen, Zhu, Wang, Ye and Gao.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.
-
Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix.Anticancer Res. 2023 Apr;43(4):1397-1405. doi: 10.21873/anticanres.16288. Anticancer Res. 2023. PMID: 36974776 Review.
-
Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.PLoS One. 2021 Nov 15;16(11):e0258605. doi: 10.1371/journal.pone.0258605. eCollection 2021. PLoS One. 2021. PMID: 34780478 Free PMC article. Clinical Trial.
-
Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.Tumori. 2022 Feb;108(1):33-39. doi: 10.1177/0300891620985309. Epub 2021 Jan 29. Tumori. 2022. PMID: 33511911
-
Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.BMC Health Serv Res. 2023 Jun 26;23(1):691. doi: 10.1186/s12913-023-09727-7. BMC Health Serv Res. 2023. PMID: 37365540 Free PMC article.
References
-
- Ahn JH, Chung JH, Lee KH, Shin KC, Choi EY, Jin HJ. Primary tracheal small cell carcinoma treated by concurrent chemoradiotherapy. Soonchunhyang Med Sci (2016) 22(2):132–5. doi: 10.15746/sms.16.030 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials